The predictors of 3- and 30-day mortality in 660 MERS-CoV patients

Ahmed, Anwar

doi:10.1186/s12879-017-2712-2

Cited by 82 publications

(100 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported disease severity and mortality risk factor data from patients in the Middle East and South Korea. 11,12,21,[114][115][116][117] Ahmed and colleagues collected the daily information on MERS-CoV cases posted online by the Saudi Arabian Ministry of Health between Dec 2, 2014, and Nov 12, 2016, and reviewed 660 laboratory-confirmed cases of MERS. 114 They showed mortality at day 3 (13·8%), day 30 (28·3%), and overall (29·8%).…”

Section: Management Outcomes and Mortality Ratesmentioning

confidence: 99%

Middle East respiratory syndrome

et al. 2020

View full text Add to dashboard Cite

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first identified in humans in Saudi Arabia and Jordan in 2012. Intermittent sporadic cases, community clusters, and nosocomial outbreaks of MERS-CoV continue to occur. Between April 2012 and December 2019, 2499 laboratory-confirmed cases of MERS-CoV infection, including 858 deaths (34·3% mortality) were reported from 27 countries to WHO, the majority of which were reported by Saudi Arabia (2106 cases, 780 deaths). Large outbreaks of human-to-human transmission have occurred, the largest in Riyadh and Jeddah in 2014 and in South Korea in 2015. MERS-CoV remains a high-threat pathogen identified by WHO as a priority pathogen because it causes severe disease that has a high mortality rate, epidemic potential, and no medical countermeasures. This Seminar provides an update on the current knowledge and perspectives on MERS epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, management, infection control, development of new therapeutics and vaccines, and highlights unanswered questions and priorities for research, improved management, and prevention.

show abstract

Section: Management Outcomes and Mortality Ratesmentioning

confidence: 99%

Middle East respiratory syndrome

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This was noted by Al‐Turaiki et al, as well . In other recent studies, being of older age was a factor for worse clinical outcomes such as infection severity and death in MERS‐CoV patients. This age group has been linked to a number of pre‐existing medical conditions and other health risks which can also increase the risk of longer recovery delay in this population.…”

Section: Discussionmentioning

confidence: 55%

“…We found that camel contact was associated with shorter recovery delay. Studies on recovery delay in patients with camel contact as compared to close contact exposure of a confirmed case or other exposure are lacking; however, camel contact has also been linked to lower 3‐ and 30‐day mortality rates in MERS‐CoV patients . This important association requires more studies to identify whether camel contact is an independent protective factor of shorter recovery delay.…”

Section: Discussionmentioning

confidence: 99%

Factors associated with recovery delay in a sample of patients diagnosed by MERS‐CoV rRT‐PCR: A Saudi Arabian multicenter retrospective study

Ahmed

Al‐Jahdali

Alaqeel

et al. 2018

Influenza Resp Viruses

Self Cite

View full text Add to dashboard Cite

BackgroundResearch evidence exists that poor prognosis is common in Middle East respiratory syndrome coronavirus (MERS‐CoV) patients.ObjectivesThis study estimates recovery delay intervals and identifies associated factors in a sample of Saudi Arabian patients admitted for suspected MERS‐CoV and diagnosed by rRT‐PCR assay.MethodsA multicenter retrospective study was conducted on 829 patients admitted between September 2012 and June 2016 and diagnosed by rRT‐PCR procedures to have MERS‐CoV and non‐MERS‐CoV infection in which 396 achieved recovery. Detailed medical charts were reviewed for each patient who achieved recovery. Time intervals in days were calculated from presentation to the initial rRT‐PCR diagnosis (diagnosis delay) and from the initial rRT‐PCR diagnosis to recovery (recovery delay).ResultsThe median recovery delay in our sample was 5 days. According to the multivariate negative binomial model, elderly (age ≥ 65), MERS‐CoV infection, ICU admission, and abnormal radiology findings were associated with longer recovery delay (adjusted relative risk (aRR): 1.741, 2.138, 2.048, and 1.473, respectively). Camel contact and the presence of respiratory symptoms at presentation were associated with a shorter recovery delay (expedited recovery) (aRR: 0.267 and 0.537, respectively). Diagnosis delay is a positive predictor for recovery delay (r = .421; P = .001).ConclusionsThe study evidence supports that longer recovery delay was seen in patients of older age, MERS‐CoV infection, ICU admission, and abnormal radiology findings. Shorter recovery delay was found in patients who had camel contact and respiratory symptoms at presentation. These findings may help us understand clinical decision making on directing hospital resources toward prompt screening, monitoring, and implementing clinical recovery and treatment strategies.

show abstract

“…Clustered hospital-acquired infections were frequently observed during the first outbreaks and probably contributed to spreading the disease from the primary site of virus infection to the whole Arabian peninsula, the most striking example of hospital-acquired outbreak being the Korean outbreak in 2015 [34]. Care providers are often affected and represent 15-22% of cases [33][34][35][36][37][38][39].…”

Section: Clinical Presentationmentioning

confidence: 99%

“…Most of the cases are described in Middle East countries, in particular Saudi Arabia (73%), with a predominance of male patients (66-69% in various studies) and a mean patient age ranging from 40 to 55 years [34,38,40].…”

Section: Clinical Presentationmentioning

confidence: 99%

Focus on Middle East respiratory syndrome coronavirus (MERS-CoV)

Bleibtreu

Bertine

Bertin

et al. 2020

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

a b s t r a c tSince the first case of human infection by the Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia in June 2012, more than 2260 cases of confirmed MERS-CoV infection and 803 related deaths have been reported since the 16th of October 2018. The vast majority of these cases (71%) were reported in Saudi Arabia but the epidemic has now spread to 27 countries and has not ceased 6 years later, unlike SARS-CoV that disappeared a little less than 2 years after emerging. Due to the high fatality rate observed in MERS-CoV infected patients (36%), much effort has been put into understanding the origin and pathophysiology of this novel coronavirus to prevent it from becoming endemic in humans. This review focuses in particular on the origin, epidemiology and clinical manifestations of MERS-CoV, as well as the diagnosis and treatment of infected patients. The experience gained over recent years on how to manage the different risks related to this kind of epidemic will be key to being prepared for future outbreaks of communicable disease. Mots clés : Maladies émergentes MERS-CoV Coronavirus Pneumonie r é s u m é Depuis le premier cas d'infection liée au Middle East Respiratory Syndrome -Coronavirus (MERS-CoV), détecté en Arabie Saoudite en juin 2012, le MERS-CoV a donné lieu, au 16 octobre 2018, à plus de 2260 cas d'infections confirmées et à 803 décès. La grande majorité des cas (71 %) ont été déclarés en ArabieSaoudite mais l'épidémie a depuis touché 27 pays et n'est toujours pas enrayée 6 ans après son émergence, contrairement au SRAS-CoV qui a disparu un peu moins de deux ans après sa première détection. En raison du taux important de décès observé parmi les patients infectés par le MERS-CoV (36 %), beaucoup d'efforts ont été déployés pour comprendre l'origine et la physiopathologie de ce nouveau coronavirus ainsi que pour lutter contre une éventuelle installation endémique de ce virus au sein de la population humaine. Cette revue s'attache plus particulièrement à retracer l'origine et l'épidémiologie du MERS-CoV à décrire la clinique observée chez les patients ainsi que la prise en charge diagnostique et thérapeutique des patients infectés. L'expérience acquise au cours des dernières années dans la gestion des différents risques liés à ce type d'épidémie est importante pour pouvoir faire face à la prochaine émergence d'infection transmissible.

show abstract

The predictors of 3- and 30-day mortality in 660 MERS-CoV patients

Cited by 82 publications

References 20 publications

Middle East respiratory syndrome

Middle East respiratory syndrome

Factors associated with recovery delay in a sample of patients diagnosed by MERS‐CoV rRT‐PCR: A Saudi Arabian multicenter retrospective study

Focus on Middle East respiratory syndrome coronavirus (MERS-CoV)

Contact Info

Product

Resources

About